Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.

Browse Complete Report Details at: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Heart failure is primarily caused by dilated cardiomyopathy (DCM). DCM commonly develops in people aged between 20 years and 60 years. DCM is one of the primary factors, which indicates the need of heart transplantation. Approximately 30% to 40% of people genetically inherit DCM. Factors such as thyroid disorders, diabetes, a viral infection in the heart valve, and alcoholism could cause DCM. As per the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy affects 6 out of 1 million children. DCM is commonly diagnosed in young children, the common diagnosis age being 2 years.

The global dilated cardiomyopathy therapeutics market is segmented on the basis of region and drug class. Some of the commonly used drug classes in DCM treatment are aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and beta blockers. In 2013, the angiotensin II receptor blockers (ARBs) segment held the largest share in the global dilated cardiomyopathy therapeutics market. In 2013, the beta blockers segment was the second largest segment in the global dilated cardiomyopathy therapeutics market.

The increasing incidence of congestive heart failure is expected to drive the global dilated cardiomyopathy therapeutics market in the coming few years. DCM accounts for 30% to 40% of congestive heart failure cases every year, reports suggest. Considering the increasing incidence of congestive heart failure, leading players have started initiating many clinical trial studies for DCM. Going forward, a global rise in the number of heart failure cases is expected to increase the demand for effective treatments. This is expected to drive the global dilated cardiomyopathy therapeutics market in the near future. The global market is expected to be hampered by the rising availability of implantable devices and the side effects of DCM drugs.

Based on geography, the global dilated cardiomyopathy therapeutics market is divided into Asia Pacific, Europe, North America, and Rest of the World. In 2013, in terms of revenue, North America held a massive share in the global dilated cardiomyopathy therapeutics market due to the increasing acceptance of branded drugs and the increasing incidences of congestive heart failure here.

Get the Premium Research Report of Dilated Cardiomyopathy Therapeutics Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Some of the key companies operating in the global dilated cardiomyopathy therapeutics market are Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and AstraZeneca plc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/